Prospective, Observational Study in Participants With Active Systemic Lupus Erythematosus (SLE) (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and At Least 2 Immunosuppressants

Bristol-Myers Squibb

Summary

The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants

Eligibility

Age range: 16+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Participants must have signed and dated an Institutional Review Board/ Independent Ethics Committee (IRB/IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines * Participants must be ≥16 years of age at the time of signing the ICF * Meet the European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) 2019 classification criteria for systemic lupus erythematosus (SLE) * Have an inadequate response to glucocorticoids and ≥ 2 immunosuppressant therapies, one of which is a biologic therapy…

Interventions

Drug
Current standard of care treatment options
According to the product label

Locations (54)

Local Institution - 0062
Mesa, Arizona
Local Institution - 0054
La Jolla, California
Local Institution - 0001
La Palma, California
Rheumatology Center of San Diego
San Diego, California
858-336-2810
Local Institution - 0063
Fort Lauderdale, Florida
Local Institution - 0061
Hollywood, Florida